Table 3. Individual study results in VDAART and COPSAC2010 and the combined analyses of the primary end-point asthma/recurrent wheeze at age 0–3.
All analyses are adjusted for gender, birth season and fish-oil intervention in COPSAC2010, and center and maternal education level in VDAART. p<0.05 is shown in italic. *Random effects meta-analysis.
| Asthma/recurrent wheeze | COPSAC2010OR (95% CI) | VDAARTOR (95% CI) | Combined analysis*OR (95% CI) |
| Active treatment | 0.76 (0.49–1.17) | 0.73 (0.53–1.00) | 0.74 (0.57–0.96) p = 0.02 |
| Stratified ≥ 30 ng/ml | 0.62 (0.34–1.13) | 0.43 (0.19–0.95) | 0.54 (0.3–0.88) p = 0.01 |
| Stratified < 30 ng/ml | 0.90 (0.49–1.67) | 0.82 (0.58–1.17) | 0.84 (0.62–1.14) p = 0.26 |
| Interaction: ≥ 30 ng/ml * vitamin D |
0.68 (0.29–1.62) | 0.57 (0.24–1.33) | 0.65 (0.36–1.20) p = 0.17 |
| Vitamin D categories: | COPSAC2010OR (95% CI) | VDAARTOR (95% CI) | Combined analysis*OR (95% CI) |
| < 30 ng/ml + placebo (ref) | 1 | 1 | |
| < 30 ng/ml + vitamin D | 0.93 (0.50–1.71) | 0.82 (0.58–1.18) | 0.85 (0.62–1.15) p = 0.29 |
| ≥ 30 ng/ml + placebo | 1.13 (0.63–2.03) | 1.01 (0.56–1.81) | 1.07 (0.71–1.62)p = 0.75 |
| ≥ 30 ng/ml + vitamin D | 0.72 (0.38–1.33) | 0.47 (0.25–0.89) | 0.58 (0.37–0.91) p = 0.02 |